newsfilter
← Latest News
ClinicalTrials.gov·

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis - NCT05123703

Annualized relapse rate (ARR), Number of new or enlarging T2-hyperintense lesions (T2 lesions) as detected by brain MRI during the double-blind period, Number of new or enlarging T2 lesions by Week 96, (and 4 more...)